Hair loss isn't random. One hormone is doing it.
That sentence is worth sitting with, because almost everything you have been sold rests on you not knowing it. Not stress. Not your shampoo. Not the hard water in your flat, not your hat, not the protein shake. In the overwhelming majority of men who are losing hair, the cause is a single androgen acting on follicles that were born susceptible to it.
What follows is the mechanism, in full — not because mechanism is interesting in itself, but because it is the only thing that tells you what can be interrupted and what cannot. Once you can see the sequence, the treatment landscape collapses into three intervention points.
It is not how much hormone you have. It is what your follicles do with it.
Testosterone circulates in every man. In certain tissues — skin, scalp, prostate — an enzyme called 5-alpha-reductase converts it into dihydrotestosterone, DHT. The enzyme comes in two main forms, type 1 and type 2, and the scalp follicle has both.
DHT is the same message as testosterone, shouted. It binds the androgen receptor with several times the affinity, and once bound it lets go far more slowly. Same key, cut deeper, turned harder, left in the lock.
Here is the part that surprises most men, and the reason a blood test is usually a waste of your money: men with androgenetic alopecia typically have entirely normal circulating androgen levels. Your testosterone is not the problem. Your DHT is, in all likelihood, unremarkable. What differs is not the hormone in the blood — it is the sensitivity of the receptor in the follicle, and how many of those receptors a given follicle carries.
The inheritance is polygenic. The androgen receptor gene sits on the X chromosome — hence the old story about your mother's father — but it is a poor predictor, and in any case it changes nothing you can act on.
The experiment that proved it is the follicle, not the scalp
In 1959 a dermatologist named Norman Orentreich moved follicles from the back of a balding man's head to the bald area on top. They kept growing — permanently, in the middle of a region where every native follicle had surrendered.
This is donor dominance, and it is the quiet proof of everything above. The follicles at the back and sides are not protected by better blood flow or a better scalp. They are simply not androgen-sensitive in the same way, and they carry their own fate with them. The scalp is not sick. A specific population of follicles is responding to an ordinary hormone in a way that is written into them.
Hair transplantation is built on this fact — and so is the reason a transplant does not stop the disease: it moves immune follicles into a battlefield while the natives keep falling.
What DHT actually does once it is inside
The androgen receptor is not a switch on the outside of the cell. It sits inside, folded up and held quiet by chaperone proteins, waiting.
DHT diffuses in and binds it. The receptor changes shape, sheds its chaperones, pairs with a second copy of itself and travels into the nucleus, where it clamps onto specific stretches of DNA — androgen response elements — and changes which genes are read, and how loudly.
The cells where this matters most sit in the dermal papilla, a small cluster at the base of the follicle. The papilla is the control room: it does not grow the hair itself, it instructs the cells that do. Turn androgen signalling up in a susceptible papilla and the instructions it broadcasts change — the molecules implicated include TGF-beta and DKK-1, which tell the surrounding keratinocytes, in effect, to stop proliferating and wind the cycle down early.
The follicle is not being poisoned. It is being told — by its own control room, in its own language — to cut the growing phase short. It complies, because that is what it is built to do.
The cycle, and how it fails
Every follicle runs a cycle, independently of its neighbours. Three phases:
- Anagen — active growth, two to six years in a healthy scalp follicle. The only phase in which hair is made.
- Catagen — a brief shutdown, two or three weeks.
- Telogen — rest, around three months, after which the old hair is released and a new anagen begins underneath.
Because anagen is measured in years and telogen in months, at any moment most of your follicles are growing and only a small minority are resting. Losing fifty to a hundred hairs a day is that minority doing its job.
Now introduce the androgen signal. With each cycle, anagen in a susceptible follicle ends sooner than it did the time before. Two years becomes one. One becomes six months. Six months becomes weeks.
And here is the consequence people miss: a hair can only grow as long as its anagen phase permits. Growth runs at roughly a centimetre a month, so a follicle with a three-month anagen can never produce a hair longer than about three centimetres — no matter how healthy you are or what you put on it. A shorter anagen also means a thinner, paler shaft, from a follicle that is itself shrinking.
Run that loop enough times and a thick, dark hair has become a short, fine, colourless one. That is miniaturisation — not hair "falling out", but hair being made smaller, cycle after cycle, until it no longer covers anything.
| Healthy follicle | Miniaturising follicle | |
|---|---|---|
| Anagen (growth phase) | 2–6 years | Shortens with every cycle |
| Maximum hair length | Long enough to cut | Capped by the shortened anagen |
| Shaft diameter | Terminal — thick | Thinning toward vellus |
| Pigment | Full | Fading |
| Proportion resting at any time | Small minority | Rises — more follicles idle, more shedding at once |
| What you see | Density | Scalp, through hair that is still technically there |
Two things follow. First: density has enormous redundancy, so you can lose a great deal of hair mass before anyone — including you — calls it hair loss. Nobody's hair loss "started suddenly." It became visible suddenly.
Second: the shedding that frightens you is a symptom, not the disease. Counting hairs in the drain tells you almost nothing. The disease is happening in the diameter of the hairs that remain.
Why it only runs one way
This is the part that decides how much time you have — and note that we gain nothing by exaggerating it.
A miniaturised follicle is still alive — still cycling, still producing something, however thin. Its papilla has shrunk and its anagen phase has collapsed, but the machinery is intact. That follicle can recover. Blunt the androgen signal and its cycle can lengthen again, its shaft thicken again. Every photograph of genuine regrowth you have seen is this: miniaturised follicles, coming back.
A follicle that has finished is another matter. What is left is a fibrous tract — scar-like tissue, no functioning structure. The best evidence available suggests bald scalp still retains hair follicle stem cells but has lost the progenitor cells those stem cells must become in order to build a hair. Whether that is one day reversible is an open question, and we are not going to pretend to answer it. What we can say is what is true today:
Nothing currently available brings back a follicle that has finished. Treatment does not turn back the clock. It stops the clock, and lets whatever is still alive come back.
So the urgency in hair loss is not a marketing device. Every month you spend deciding, some number of follicles cross from the column that can still recover into the column that cannot. That number may be small. It is not zero, and it is not refundable.
That isn't a sales tactic. It's arithmetic.
Three places you can interrupt this — and only three
Look at the chain again: testosterone → 5-alpha-reductase → DHT → androgen receptor → shortened anagen → miniaturisation. Every real intervention attacks one of three points on it. Everything else — caffeine shampoos, biotin, rosemary oil, derma rollers on their own — operates somewhere off this diagram, which is precisely why none of it holds a hairline.
Disclosure, before the list. One of these three is the category we sell into: we make RU-58841 5%, blended in our own lab in the EU. It is a research compound, not an approved medicine. Read the rest knowing we have an interest.
1. Make less DHT — the 5-alpha-reductase inhibitors
Finasteride blocks type 2 of the enzyme; dutasteride blocks both and lowers DHT further. Prescription medicines, and the largest evidence base in the field. They are also systemic — DHT falls everywhere, not only where you want it. That is the trade that sends most men looking for something else.
2. Block the receptor — topical androgen receptor antagonists
This one leaves your hormones where they are and goes after the lock instead of the key. An antagonist occupies the receptor without activating it: DHT arrives, finds the seat taken, and the instruction to cut anagen short is never transmitted. The disease is local, so the intervention could be local. This is the category RU-58841 belongs to.
3. Push growth — minoxidil
Minoxidil touches neither the hormone, the enzyme, nor the receptor. It acts downstream, extending the growth phase by a mechanism still not completely understood. It works — it is approved, it has the trials — but it works against a signal it never turns off.
It is the accelerator, not the brake — you end up growing hair into a headwind.
Set the three side by side and the logic of combining stops looking commercial and starts looking obvious. A brake and an accelerator are not competitors, and no single lever addresses the whole chain — each carries a cost the other two do not. We take all three apart, with the evidence for each, in RU-58841 vs finasteride vs minoxidil.
What we know about RU-58841, and what we do not
RU-58841 is a nonsteroidal androgen receptor antagonist. CAS 154992-24-2. It came out of Roussel-Uclaf — the RU is the company — and was designed to be applied to skin and act where it lands: antagonising the receptor locally while being broken down rather than accumulating systemically. In animal models it did what it was designed to do. It never became an approved medicine, and why it stopped is not publicly documented in any form we would defend.
So here is the position, stated plainly, because you will not get it from most people selling this compound:
- It is a research compound. It is not an approved medicine, anywhere.
- There are no large human trials. They were not run — so no one can honestly quote you a figure for how often it works, or how often something goes wrong.
- What exists in humans is anecdote. Some of it is careful, photographed and honest. It is still anecdote, and anecdote cannot give you a rate.
- Anyone who tells you it is free of side effects is telling you something they cannot know.
We sell this compound and we are telling you this anyway, because the alternative is to pretend an evidence base exists — and you would find out. The mechanism above is solid. What is missing is the human trial data, and no amount of confident copywriting manufactures it. The full head-to-head is in RU-58841 vs finasteride vs minoxidil.
What we can be held to. We blend RU-58841 5% ourselves, in the EU. Not bought in, not rebottled, not dropshipped from an address that will not answer you. The batch number, the date it was blended and the date it expires are printed on the bottle you receive — so you can always answer "how old is this?", which is the question that actually matters for a compound that degrades in time and light. It ships from inside the EU: days, not weeks, in a box that says nothing about what is in it. Sold for laboratory research.
RU-58841 5% — what's in the bottle
What to do with this
Nothing in this article tells you what to put on your head. That is deliberate: we are a laboratory, not a clinic, and the compound we are best known for is not an approved medicine — printing a protocol for it would mean inventing an authority we do not have.
What the mechanism does tell you is how to think:
- The cause is a hormone at a receptor, in follicles that inherited a sensitivity to it. Nothing that fails to touch that chain will hold your hairline.
- Miniaturised follicles can recover. Finished ones cannot. The clock is the adversary — not the mirror.
- Anything that works, works only while you use it. Stop, and the follicles resume the trajectory they were on.
- You cannot judge this by feel. Six months is the earliest point a fair judgement is possible. Compare photographs, not memories.
That last point ruins more attempts than anything else, so we wrote it out in full: the hair loss timeline, month by month. For the cheapest, lowest-risk thing on the board while you decide, read what ketoconazole shampoo does and does not do.
Folliva Labs formulates topical research compounds in the EU. This article is a description of published mechanism and evidence, not medical advice, and not a claim that any product prevents, treats or cures any condition. RU-58841 is sold for laboratory research: not for human or veterinary use. Androgenetic alopecia is a medical diagnosis — if you want one, see a doctor.